Skip to main content
SpringerLink
Log in

Modern Approaches in Cancer Pharmacology

  • Chapter
  • First Online:
Book cover Drug Design: Principles and Applications

  • 1331 Accesses

Abstract

Cancer, known by many names including Carcinoma, Malignancy, Neoplasms and Tumor is the leading cause of death worldwide. Depending on the anatomical part of human body, Cancer can be named as lung cancer, pancreatic cancer, breast cancer etc. Owing to the present lifestyle, the burden of leading cause of death in economically developed countries is expected to rise. Several factors including environmental, smoking or tobacco, consumption of alcohol, dietary routine, radiation and infections have a profound impact on most cancers than hereditary factors. Evidently, although hereditary factors cannot be altered, lifestyle and environmental factors can be modified which might be a step towards prevention of cancer. Modern treatment methods of cancer include a multimodal approach rather than replacing the conventional treatment methods completely. This chapter will provide an input of various treatment methods employed to combat cancer and the modern approaches being considered to counter the various problems associated with cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108

    Article  PubMed  Google Scholar 

  2. Ames BN, Gold LS, Willett WC (1995) The causes and prevention of cancer. Proc Natl Acad Sci 92:5258–5265

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Michalas SP (2000) The Pap test: George N. Papanicolaou (1883–1962): a screening test for the prevention of cancer of uterine cervix. Eur J Obstet Gynecol Reprod Biol 90:135–138

    Article  CAS  PubMed  Google Scholar 

  4. Tabar L, Gad A, Holmberg L, Ljungquist U, Group KCP et al (1985) Reduction in mortality from breast cancer after mass screening with mammography: randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 325:829–832

    Article  Google Scholar 

  5. Whipple AO (1950) Radical surgery in the treatment of cancer. Ann Surg 131:812

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Keevil G (1896) The Roentgen rays. Br Med J 1:433

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Wolf GT, Hong WK, Fisher SG, Urba S, Endicott JW et al (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685–1690

    Article  PubMed  Google Scholar 

  8. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85:304–313

    Article  CAS  PubMed  Google Scholar 

  9. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Grillo-López AJ, White CA, Varns C, Shen D, Wei A et al (1999) Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 26(5 Suppl 14):66–73

    PubMed  Google Scholar 

  11. Slamon D, Pegram M (2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28(1 Suppl 3):13–19

    Article  CAS  PubMed  Google Scholar 

  12. Sawyers C (2004) Targeted cancer therapy. Nature 432:294–297

    Article  CAS  PubMed  Google Scholar 

  13. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    Article  CAS  PubMed  Google Scholar 

  14. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266:1821–1828

    Article  CAS  PubMed  Google Scholar 

  15. Yu H, Jove R (2004) The STATs of cancer—new molecular targets come of age. Nat Rev Cancer 4:97–105

    Article  CAS  PubMed  Google Scholar 

  16. Fraley ME, Arrington KL, Bilodeau MT, Hartman GD, Hoffman WF, et al (2004) Tyrosine kinase inhibitors. Google Patents

    Google Scholar 

  17. Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315:971–979

    Article  CAS  PubMed  Google Scholar 

  18. Shawver LK, Slamon D, Ullrich A (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1:117–123

    Article  CAS  PubMed  Google Scholar 

  19. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615–2622

    CAS  PubMed  Google Scholar 

  20. Wang HF, Feng B, Sun Y, Tang GB, Min J et al (2013) Proteasome inhibitor Brotezomib induces apoptosis of colon cancer cells SW480 through inhibiting PI3K/Akt pathway. Prog Mod Biomed 11:013

    CAS  Google Scholar 

  21. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–30

    Article  CAS  PubMed  Google Scholar 

  22. Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359–1364

    Article  CAS  PubMed  Google Scholar 

  23. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ et al (2003) A randomized trial of bevacizumab, an anti–vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD et al (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66:357–371

    Article  CAS  PubMed  Google Scholar 

  25. Lu L, Payvandi F, Wu L, Zhang L-H, Hariri RJ et al (2009) The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77:78–86

    Article  CAS  PubMed  Google Scholar 

  26. Frei E, Freireich EJ, Gehan E, Pinkel D, Holland JF et al (1961) Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate. Blood 18:431–454

    Google Scholar 

  27. Wood AJ, Gorlick R, Goker E, Trippett T, Waltham M et al (1996) Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335:1041–1048

    Article  Google Scholar 

  28. Goyal S, Jamal S, Shanker A, Grover A (2015) Structural investigations of T854A mutation in EGFR and identification of novel inhibitors using structure activity relationships. BMC Genomics 16:S8

    Article  PubMed  PubMed Central  Google Scholar 

  29. Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M et al (2008) Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 14:7519–7525

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Nie S (2010) Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine 5:523–528

    Article  PubMed  PubMed Central  Google Scholar 

  31. Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649–1659

    Article  CAS  PubMed  Google Scholar 

  32. Jackson SE, Chester JD (2015) Personalised cancer medicine. Int J Cancer 137:262–266

    Article  CAS  PubMed  Google Scholar 

  33. Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3:673–683

    Article  CAS  PubMed  Google Scholar 

  34. Tobinick EL (2009) The value of drug repositioning in the current pharmaceutical market. Drug News Perspect 22:119–125

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

AG is thankful to Jawaharlal Nehru University for usage of all computational facilities. AG is grateful to University Grants Commission, India for the Faculty Recharge Position. SG acknowledges the Young Scientist Fellowship from Department of Health Research (DHR), New Delhi.

Competing Interests

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

  1. School of Biotechnology, Jawaharlal Nehru University, New Delhi, 110067, India

    Sukriti Goyal & Abhinav Grover

  2. Department of Bioscience and Biotechnology, Banasthali University, Tonk, Rajasthan, 304022, India

    Sukriti Goyal

Authors
  1. Sukriti Goyal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abhinav Grover
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abhinav Grover .

Editor information

Editors and Affiliations

  1. School of Biotechnology, Jawaharlal Nehru University, New Delhi, India

    Abhinav Grover

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Goyal, S., Grover, A. (2017). Modern Approaches in Cancer Pharmacology. In: Grover, A. (eds) Drug Design: Principles and Applications. Springer, Singapore. https://doi.org/10.1007/978-981-10-5187-6_3

Download citation

Publish with us

Policies and ethics

Search

Navigation